Since 1996 our electrophysiological diagnostic catheters and ablation catheters have been submitted to a certified (DIN EN ISO 13485) reprocessing company (Remed GmbH ® , a member of the VANGUARD group). Each step of reprocessing that the catheters have to pass is certified according to the existing international regulations (standards, guidelines, etc.), which is required by law in Germany 1,2 and is in
accordance with EU laws and guidelines. These regulations demand that reprocessed medical devices have the same safety and performance levels as new products. All processes are included in the quality management of the company and the hospital.
The manufacturing industry had repeatedly claimed that the reuse of catheters could have serious disadvantages for patients, or that the reprocessing of such devices represented an unbearable risk. We therefore decided to evaluate the potential risks of reused products in clinical electrophysiology in a prospective registry in 2000 and 2003. The registry was in the scope of our quality management system; ablations were performed using new ablation and diagnostic catheters as well as catheters reprocessed by an industrial partner. The aim of the study was to detect potential differences between both lines in terms of risks and procedural outcome in patients.
Methods
It could be assumed that reprocessing would alter the properties of the material or the function of the catheter in such a way that the examination might become more difficult, which in turn would result in a deterioration of various specific performance parameters. For example, changes in the torque and push stability of a catheter could lead to placement difficulties, meaning that the duration of the examination and fluoroscopy time would be increased compared with new catheters. If the tip electrode of the catheter cannot be placed in a stable position on the endocardial point of intended ablation, numbers of radiofrequency (RF) deliveries may increase. Based on these considerations, we assessed 202 catheter interventions in patients, in whom about an equal number of new electrophysiological catheters and catheters that had been reprocessed were used. The register was prospective. Samples were drawn at consecutive days by a non-medical responsible technician.
Reused catheters were drawn without any preselection from the hospital storage out of 356 available recycled and 298 new catheters. The number of reprocessing turns (one to six times) was read from the barcode of the catheter and entered into the data collection sheet after an ablation procedure was finished. This number was unknown to the sampledrawing technician and the medical doctor responsible for the procedure.
Limitations
There are some limitations to the study, to be mentioned below. The reported data are part of a quality management register of both VANGUARD and the Kerckhoff-Klinik Bad Nauheim. The study should not be considered randomised. The technician collecting the samples was independent and unaware of the success of the ablation, any difficulties encountered during the procedure or late results of the six-month followup. The medical doctors examining the patients at follow-up did not know whether the patients had been treated with new or reused catheters. The follow-up investigations were part of a quality-control programme conducted by the Kerckhoff-Klinik Bad Nauheim, the cardiology department of the University of Frankfurt and the medical services of statutory health insurance bodies in the federal state of Hesse (MDK Hesse), Germany. The results regarding complications and success rates of RFenergy ablation of arrhythmias were audited by a sample-drawing medical doctor from MDK Hesse. It must be emphasised that testing the use of new or reprocessed catheters was not the primary goal of this quality management contract, but it may reflect steps to ISO 9001. Investigations with a multicentre, randomised study controlled by EU or German independent certifying authorities are desirable to deliver further results.
The following specific parameters (primary end-points of the registry) were recorded and assessed for a total of 202 patients:
• procedure time (min);
• fluoroscopy time (min);
• number of RF energy deliveries (n);
• severe procedure-related complications -pericardial effusion or tamponade, third-degree atrioventricular (AV) block, peri-procedural thromboembolic event or intention to treat related death; and
• recurrence of arrhythmia during the first six months after ablation.
The procedure time was calculated from the moment the patient was placed on the examination table to the retransferral of the patient after the procedure. The fluoroscopy time refers to the duration of the necessary X-ray fluoroscopy carried out in order to perform the catheter ablation. A further important parameter recorded was the number of RF energy deliveries for each intervention, which is a marker of catheter stability at the location of ablation. Procedure-related complications were picked up over a time period of six months. For the statistical analysis of continuous variables, for unpaired samples a t-test was used and for categorical variables Fischer's exact p was used. All values are given as mean. The differences were considered as significant by an error probability of 5%. Statistical testing was performed for the whole sample because subgroups of different procedures were too small and too imbalanced for statistical purposes. ablation (see Figure 4 ), WPW ablation (see Figure 5 ) and AVNRT ablation (see Figure 6 ). Imbalances in the subgroups were too high for statistical testing.
Results

Table
Follow-up Examinations
In follow-up examinations, the recurrences of arrhythmia or complications up to discharge and after a period of six months were recorded for the reused catheters (see Figure 7 ) and new catheters (see The number of early recurrences (during hospitalisation) after ablation using new catheters were 3/100 patients, and 4/100 patients at the six-month follow-up. The results for reprocessed catheters were 4/102 early recurrences and 2/102 at follow-up. Therefore, recurrences during follow-up were observed in 7% of patients using new catheters versus 6.9% of those using reprocessed catheters: again, there was no significant difference (see Table 2 ).
Results From 2000 Verified
These results confirmed the data gained from a similar comparative -but smaller -study that we performed in 2000. 3 In the 2000 study we assessed the specific parameters of examinations carried out on a total of 110 patients. Fifty patients had been treated with reprocessed catheters and 60 patients with new ones. The results of this study are shown in The results match our experience -i.e. no significant differences were found between catheters that were used just once and catheters that were reused after reprocessing by a professional reprocessor (VANGUARD).
Discussion
Although our data presentation includes the limitations outlined above, the quality management processes of VANGUARD and our clinic did not for this is that the quality of new catheters has improved dramatically since the beginning of the 1980s. This is a result of the growing market for interventional electrophysiology, improved internal quality management at the manufacturers and the increasing safety and effectiveness controls installed by governments in and outside the US.
The desire to sell single-use catheters is understandable when one considers development costs, regulatory risks and further financial interest. However, there is a conflict of interests here. Societies want to offer optimal medical treatment to all those who need it, as safely as possible and at a price that can be covered by that country's economic power. Opponents of reprocessing repeatedly claim that the reprocessing of single-use medical devices bears an increased risk, and that the safety and health of patients is thus endangered. However, our results show that this is not the case.
Material changes that occur during the course of preceding applications and reprocessing seemed to be clinically irrelevant and influence neither the course of the procedure nor late results. This means that the high quality provided by the original equipment manufacturers allows the treatment of a larger number of patients who ask for optimal treatment of their disease.
Reprocessing By a Certified Reprocessor
The prerequisite for excellent results is that reprocessing is performed at a high standard, comparable to the quality management of original equipment manufacturers. The decisive factor is that the safety goals 
